1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program is an initiative under the European Innovation Council (EIC) aimed at supporting small and medium-sized enterprises (SMEs) and startups in their pursuit of breakthrough innovations. Designed specifically for high-risk, high-potential startups, the program aims to catalyze the European economy by fostering deep technology advancements. It provides substantial funding options that can include grants and equity investments tailored to the needs of innovative companies.

Funding Structure

The EIC Accelerator funding is divided into two primary components: grants and equity investments. The grants can reach up to €2.5 million, offering financial support to cover prototyping, testing, and other early-stage development activities. This grant funding is intended to reduce the financial burden on companies as they navigate the crucial early phases of innovation.

In addition to grants, the EIC Accelerator provides equity funding that can be critical for scaling operations. Until 2024, companies can access equity investments of up to €15 million, which can substantially boost the financial capacity for commercialization and scaling. Starting in 2025, this equity funding will be capped at €10 million. This tiered funding system allows companies to leverage public funding while also attracting private sector investments, thereby creating a more sustainable pathway to growth.

Purpose of the EIC Accelerator

The EIC Accelerator serves a vital role in the European DeepTech and startup ecosystem by bridging the funding gap that often exists for innovative companies. Many startups struggle to secure private investment due to the high risks associated with developing groundbreaking technologies. The EIC Accelerator mitigates this risk by providing initial funding, which serves as a proof of concept and encourages further investments from private investors.

By supporting companies at various stages of their development, the EIC Accelerator helps to create a robust innovation landscape in Europe. This not only spurs economic growth but also fosters the development of cutting-edge technologies that address pressing societal challenges.

Role in Scaling Companies

The EIC Accelerator plays a crucial role in helping companies scale by providing them with the necessary resources and support to navigate the commercialization process. The combination of grants and equity funding allows companies to invest in critical areas such as product development, market entry, and scaling operations. Additionally, the program offers access to extensive networks of investors, mentors, and industry experts, enhancing the company’s ability to attract further investment and accelerate growth.

Case Study: Vigor Medical Technologies LTD

Company Overview: Vigor Medical Technologies LTD, based in Israel, emerged as a winner of the EIC Accelerator with its innovative project, the C-LANT Drainage Port. The project focuses on life-saving technology for thoracic trauma treatment and post-operative drainage.

Project Description: The C-LANT Drainage Port project addresses critical medical needs associated with thoracic trauma, a condition that can lead to life-threatening complications if not managed effectively. The technology aims to improve the efficiency and safety of drainage procedures, which are essential in treating patients with chest injuries or post-operative complications.

Technology Basics: The C-LANT Drainage Port employs advanced engineering principles to create a more effective drainage system. Traditional drainage methods often involve complications such as tube blockage, infection risk, and inadequate drainage efficiency. The C-LANT technology seeks to overcome these issues by incorporating innovative design features that enhance fluid dynamics and minimize the risk of infection.

The system is designed to ensure optimal drainage while being less invasive and easier to manage for healthcare professionals. By improving the safety and efficiency of thoracic drainage procedures, the C-LANT Drainage Port has the potential to significantly improve patient outcomes and reduce healthcare costs associated with complications.

Funding Journey: Vigor Medical Technologies submitted its Step 2 proposal for the EIC Accelerator on October 5, 2022, and successfully advanced to the Step 3 interview, securing grant funding to further develop the C-LANT Drainage Port. This funding will enable the company to refine its technology, conduct clinical trials, and prepare for market launch.

In summary, the EIC Accelerator program plays a pivotal role in supporting innovative companies like Vigor Medical Technologies, providing them with the necessary funding and resources to scale their transformative technologies in the healthcare sector. The successful development of the C-LANT Drainage Port exemplifies the impact of the EIC Accelerator in propelling groundbreaking medical solutions forward.

2 The Funding Rounds

Financing Raised

Since receiving the EIC Accelerator funding, Vigor Medical Technologies Ltd (Israel) has raised a total of approximately $2.6 million across four funding rounds. This figure includes both equity investments and grant funding, notably the European Innovation Council (EIC) Accelerator grant of €2.5 million awarded in 2023.

Funding Rounds: Timing and Amounts

• April 2021: Vigor Medical Technologies closed an equity round led by Springtide Investments, with participation from a professional VC syndicate based in Austin, Boston, Hong Kong, and Singapore.
• October 2022: The company was selected for the EIC Accelerator program and subsequently secured €2.5 million (~$2.7M at contemporary exchange rates) in non-dilutive grant funding from the European Innovation Council.
• Other Rounds: While additional grants or smaller investments are referenced (such as participation in accelerators like MassChallenge), specific amounts for those rounds are not detailed beyond aggregate totals.

Investor Information

Springtide Investments is identified as a lead investor during the April 2021 equity round; other investors included VCs from Austin, Boston, Hong Kong, and Singapore. Recent communications also reference institutional support from Technion – Israel Institute of Technology – and Israel's Ministry of Defense as investors or supporters by October 2024. Verge HealthTech Fund is listed as an early backer since September 2019.

Additional Funding Round Details

The company’s fundraising approach has combined competitive public grants (notably through EU/EIC mechanisms) with traditional venture investment focused on medtech innovation for trauma care. Several awards were also received through accelerator programs such as MedTech Innovator APAC and MassChallenge USA/Boston—these typically provide modest sums or convertible notes alongside mentorship but are not always reflected in headline fundraising totals.

Company Valuation

Specific valuation figures have not been publicly disclosed by either the company or third-party data providers to date; major databases list market cap/valuation status as "undisclosed".

Exit Events: IPOs & Acquisitions

As of May 2025:

• There is no record that Vigor Medical Technologies has undergone an initial public offering (IPO).
• There is no public information indicating any acquisition or buyout event involving this company.

All available evidence points to continued independent operation with growing investor interest but without exit events completed so far.

---

Sources

• News — Vigor Health - Vigor Medical Systems
• Vigor Medical Technologies - Startup Nation Finder
• Vigor Medical Technologies company information, funding ...
• News & Events - VIGOR Medical Technologies
• Vigor Medical Technologies Financials - Startup Nation Finder
• Vigor Medical Technologies Stock Price, Funding ... - CB Insights

3 The Press Releases

Overview of Vigor Medical Technologies LTD

Vigor Medical Technologies LTD, based in Israel, achieved significant recognition by winning the European Innovation Council (EIC) Accelerator funding in October 2022. This prestigious award highlights the company's innovative approach to medical technology, particularly in developing life-saving devices.

EIC Accelerator Funding

Vigor Medical Technologies received €2.5 million in funding through the EIC Accelerator program. This funding is crucial for advancing its medical technologies, such as the C-LANT Drainage Port, which is a life-saving technology for chest trauma treatment.

Technology Advancements

The company focuses on developing technologies for treating chest trauma, with potential applications in other areas like abdominal ports and emergency medical services (EMS) devices. Vigor Medical Technologies is also exploring additional indications for its technology, including thoracic ports for non-drainage applications and devices for laparoscopic robotic surgery and neurosurgery.

Team Updates

The company's leadership includes experienced professionals from the medtech industry. For example, Lena Cavenoffski has over 20 years of experience in medtech companies, VCs, and hospitals. Iniga Wiseman has over 35 years of experience and holds numerous patents. Dr. John Abolist, a doctor with significant experience in private and public healthcare companies, also contributes to the team.

Patents

While specific details on recent patents are not highlighted, Vigor Medical Technologies' involvement in innovation suggests continuous efforts in intellectual property development.

Press Releases and Updates

There are no specific press releases on Vigor Medical Technologies' website detailing recent partnerships or technology advancements directly related to the EIC funding. However, the company has been recognized for its innovative work, such as winning the prestigious ICI Meeting Innovation Award in Israel and participating in various international competitions and innovation events.

Social Media and Website Updates

The company does not appear to have a robust social media presence focused on press releases. However, its achievements and participation in significant events are noted in various external sources.

Sources: - EIC Accelerator winners and statistics October 2022

• News & Events - VIGOR Medical Technologies
• Avi Hirsch Presents Vigor Medical at LSI Europe '23

4 The Technology Advancements

Vigor Medical Technologies LTD: Current Capabilities and Advancements

Vigor Medical Technologies LTD, an Israeli company, specializes in developing innovative, life-saving devices and AI-driven solutions, particularly for chest trauma and thoracic/abdominal drainage. Since receiving the EIC Accelerator funding in October 2022, Vigor Medical has made significant advancements in its technology and market presence.

Current Capabilities

Vigor Medical's primary focus is on developing and commercializing life-saving devices for treating chest trauma. One of its key innovations is the C-LANT device, designed to revolutionize chest trauma management by providing immediate intervention within the critical "Golden Hour," significantly increasing survival chances. C-LANT allows for rapid self-fixation to the body, creating a hermetic channel for standard chest tubes and other instruments, reducing drainage time by up to 20 times.

Advancements Since EIC Funding

Following the EIC Accelerator funding, Vigor Medical has expanded its technological capabilities and market strategy. The company received non-dilutive funding of $2.7 million from the EIC and is seeking additional investments to enhance its product pipeline. Vigor Medical is planning to expand its offerings to include abdominal ports and other applications like laparoscopic robotic surgery and neurosurgery, aiming to increase its market reach. The company expects to become profitable by 2027 and achieve revenues of $67 million by 2030.

Technology Improvements and New Features

Vigor Medical continues to enhance its C-LANT technology, focusing on improving its efficiency and expanding its use cases. While specific new features have not been detailed, the company's goal is to leverage its AI-driven solutions to enhance emergency medical services (EMS) and improve patient outcomes.

Market Demonstration and Clinical Trials

There is no specific information available on whether Vigor Medical has conducted clinical trials or pilots since receiving the EIC funding. However, the company has expressed enthusiasm from various medical professionals to start using its technology once approved. Vigor Medical participates in industry events and conferences, such as LSI Europe '23, where it presents its technology and future plans.

Patents and Scientific Studies

There is no recent information on new patents filed or scientific studies published by Vigor Medical. However, the company's focus on innovative medical devices suggests ongoing research and development efforts.

Conclusion

Vigor Medical Technologies LTD has made significant strides in developing life-saving medical devices, particularly for chest trauma management. With the support of the EIC Accelerator funding, the company is poised to expand its product offerings and enhance its market presence in the coming years.

Sources:

• VIGOR Medical Technologies
• 19 women are in the running for the 2025 European Prize for Women Innovators
• News & Events - VIGOR Medical Technologies
• Avi Hirsch Presents Vigor Medical at LSI Europe '23
• Vigor Medical Technologies
• Vigor Medical – C-LANT - Evolution Europe

5 The Partnerships and Customers

Vigor Medical Technologies Ltd. Strategic Partnerships and Market Positioning Post-EIC Accelerator

Since securing €2.5 million in EIC Accelerator funding in August 2023, Vigor Medical Technologies Ltd. has expanded its collaborations with military, academic, and clinical partners to advance its thoracic trauma solutions. Key developments include:

---

Key Partnerships and Collaborations

• Military Health Systems:
• Worked with the Israel Defense Forces (IDF) Medical Corps, Institute for Research in Military Medicine, and Hebrew University of Jerusalem to conduct animal trials for its C-LANT Drainage Port Device.
• Presented research at the U.S. Military Health System Research Symposium (MHSRS), highlighting applications for battlefield trauma care.
• Clinical Validation Partners:
• Completed a retrospective clinical trial at Ziv Medical Centre (Safed, Israel) to validate real-world efficacy of its drainage technology.
• Collaborated with Hadassah Hebrew University Medical Center (Jerusalem) on preclinical studies.
• Academic and Innovation Ecosystems:
• Selected for the fifth cycle of Israel’s defense-tech innovation hub INNOFENSE (November 2024), aimed at scaling dual-use medical technologies for military-civilian markets.
• Secured investments from the Israeli Ministry of Defense and Technion Institute, aligning with national priorities for combat-medical innovation.

---

Strategic Impact on Market Positioning

Vigor’s partnerships reinforce its role as a leader in portable trauma care solutions:

• Dual-Use Technology Adoption: INNOFENSE participation positions Vigor to commercialize devices across military EMS and civilian emergency services globally.
• Regulatory Acceleration: Clinical trials at Ziv and Hadassah provide data to expedite regulatory approvals in target markets like the U.S. and EU.

---

Technological Advancements Through Collaborations

Joint efforts have driven innovations such as:

• The AI-enhanced C-LANT system designed for rapid deployment in resource-limited environments, reducing complications from chest trauma.
• Integration of battlefield feedback from IDF medics into product iterations, enhancing usability under fire.

---

Future Scaling Pathways

New relationships provide access to:

• Military procurement channels via INNOFENSE’s defense networks.
• Academic R&D pipelines through Hebrew University collaborations to refine AI-driven drainage protocols [^animal-trials-footnote].

---

Sources Used:

<div class="bullet-item"><span class="bullet-point">•</span> <a href="https://www.vigormt.com/newsevents" class="inline-link" target="_blank" rel="noopener noreferrer">News & Events - VIGOR Medical Technologies</a> • <a href="https://finder.startupnationcentral.org/company_page/vigor-medical-technologies" class="inline-link" target="_blank" rel="noopener noreferrer">Vigor Medical Technologies Company Profile</a> • <a href="https://www.vigormt.com" class="inline-link" target="_blank" rel="noopener noreferrer">VIGOR Official Website</a></div>

Note: No direct customer names are disclosed publicly; partnerships focus on R&D validation.

---

[^animal-trials-footnote]: Successful animal trials were conducted jointly with Hebrew University’s Faculty of Medicine teams specializing in combat-injury models.

6 The Hiring and Company Growth

Vigor Medical Technologies LTD: Growth and Development Since EIC Accelerator Funding

Vigor Medical Technologies LTD, based in Israel, received the EIC Accelerator funding in October 2022. Since then, the company has been at the forefront of developing innovative, life-saving devices and AI-driven solutions for chest trauma and thoracic/abdominal drainage.

Current Team and Hiring

While specific details about the current team size or headcount are not available, Vigor Medical Technologies is led by a strong founding team that includes Irina Kavounovski as CEO and Co-Founder, Igor Waysbeyn as CTO and Co-Founder, and Dr. John Abeles as Co-Founder. The company's management and founding team have remained consistent, with no major changes reported.

Regarding hiring, Vigor Medical Technologies is likely to be expanding its team to support its growth objectives, especially given its recent achievements and funding. However, there is no explicit information available on whether they are currently hiring or specific positions they have recently filled.

Growth and Development

Since receiving the EIC funding, Vigor Medical Technologies has continued to innovate and expand its product offerings. The company's flagship product, the C-Lant Port, aims to effectively treat chest trauma, inflammatory lung diseases like pneumonia, and post-operative drainage. With a potential market size exceeding $2 billion, Vigor Medical Technologies plans to reach the market within 18-24 months.

Impact of New Team Members

New team members would play a crucial role in helping Vigor Medical Technologies scale and grow. They would contribute to product development, regulatory approvals, and market preparation, which are essential for the company's future success. The addition of skilled professionals could enhance the company's ability to navigate complex regulatory environments, such as obtaining FDA and CE approvals, and expand its market presence.

Future Outlook

Vigor Medical Technologies' future looks promising, with its innovative solutions poised to make a significant impact in the medical technology sector. The company's focus on developing life-saving devices aligns with growing global healthcare needs, particularly in emergency medical services and hospital settings. As Vigor Medical Technologies continues to grow and expand its offerings, it is likely to become a key player in the thoracic trauma and post-operative drainage market.

Sources

• VIGOR Medical Technologies
• Vigor Medical Technologies - Startup Nation Finder
• Our Team - VIGOR Medical Technologies
• Vigor Medical Technologies Ltd. Information - RocketReach
• Vigor Medical Technologies - EuroQuity

7 The Media Features and Publications

Vigor Medical Technologies Ltd., an Israeli company specializing in life-saving medical devices, particularly for chest trauma and thoracic/abdominal drainage, has garnered significant media attention, publications, event participations, and industry recognition since winning EIC Accelerator funding in October 2022.

Media Features and Publications

• Vigor Medical is frequently highlighted as an innovative startup developing the C-Lant device—a proprietary self-fixation sealing device designed to treat chest trauma effectively. This device aims to improve emergency medical services (EMS), including military and civilian first aid.
• The company was featured in Israel21c in 2016 for its revolutionary lifesaving technology that could transform treatment of the leading cause of accidental death worldwide—chest trauma. The article detailed how Vigor’s father-daughter founding team developed C-Lant with input from international specialists and tested it extensively with animal models at Hebrew University alongside the Israeli Defense Forces (IDF).
• Vigor Medical’s scientific research includes successful animal trials conducted at Hebrew University (Jerusalem) and retrospective clinical trials completed at Ziv Medical Centre in Safed, Israel.
• Their innovation has been recognized by prestigious awards such as “The most innovative Start-Up Company in Israel” at iNNOVEX Startup Competition, winner of ICI Meeting Innovation Award (Israel), runner-up at Shenzhen International Talents Competition among hundreds of companies from multiple countries, finalist status at Innovation Days Event (France), and others.

Podcasts or Interviews

While specific podcasts or interviews featuring Vigor Medical's team were not explicitly found within the search results, their participation in prominent forums such as McKinsey Early Stage Investor Conferences suggests they have engaged publicly to share their vision with business executives and investors.

Conference Participation and Presentations

Vigor Medical Technologies has actively participated in various international conferences:

• Presentation by Dr. Dinesh Shah at Euro PCR conference (France)
• Presentation by Dr. Seema Biswas at Israeli Surgery Meeting
• Annual Anesthesiology Conference presentation by Dr. Ruth Shaylor (Israel)
• Poster presentation at Military Health System Research Symposium MHSRS (USA)

Additionally:

• Participation in Inventech Program (Haifa) with grant support for 2023–2024
• Completion of T-Factor Acceleration Program from Technion Institute
• Completion of MassChallenge Acceleration program based out of Boston USA

These activities highlight ongoing scientific engagement both domestically within Israel and internationally.

Involvement With Events

Vigor Medical has been involved not only through presentations but also through recognition events:

Winner accolades include iNNOVEX Disrupt Competition Israel 2016; runner-up status among global talent competitions; selected as a Deep Tech Pioneer by Hello Tomorrow Paris; part of MedTech Innovator Asia Pacific Accelerator cohort; Verge HealthTech Fund Portfolio Company supporting sustainable healthcare innovations globally.

They also maintain active communication channels on their website showcasing news updates about grants received, patent awards granted both US & European patents related to digital pulmonary management technologies along with clinical outcome achievements reported for US programs launched commercially abroad like India chronic respiratory disease management program launched October 2022.

---

Overall, since receiving EIC Accelerator funding post their submission on October 5th, 2022, Vigor Medical Technologies Ltd continues building its profile via media features praising its breakthrough C-Lant device innovation; participating actively across major medtech conferences internationally; earning scientific publication credits linked to clinical validation studies performed collaboratively with top-tier academic institutions; engaging investor conferences highlighting future market potential especially focusing on EMS sectors globally.

Sources:

VIGOR Medical Technologies Official Website
DNB Business Directory Profile
Gust Profile – Vigor Medical Technologies
VIGOR News & Events Page
ISRAEL21c Article - Novel Device Boosts Survival Chances After Chest Trauma